CD14 Positive Extracellular Vesicles in Broncho-Alveolar Lavage Fluid as a

New Biomarker of Acute Respiratory Distress Syndrome

Rahul Y. Mahida¹, Joshua Price², Sebastian T. Lugg¹, Hui Li^{1,3}, Dhruv Parekh¹, Aaron Scott¹, Paul Harrison², Michael A. Matthay⁴, David R. Thickett¹.

¹Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, U.K.

²Institute of Inflammation and Ageing, University of Birmingham, Birmingham, U.K.

³Department of Anesthesia and Critical Care, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Zhejiang, China

⁴Cardiovascular Research Institute, Department of Medicine, and Department of Anesthesia, University of California San Francisco, San Francisco, California, U.S.A.

Corresponding Author: Dr Rahul Y. Mahida

Institute of Inflammation and Ageing, University of Birmingham, Birmingham, B15 2TH, U.K.

Email: r.mahida@bham.ac.uk

ABSTRACT

Recent studies have indicated that extracellular vesicles (EV) may play a role in the

pathogenesis of Acute Respiratory Distress Syndrome (ARDS). EV have been identified as

potential biomarkers of disease severity and prognosis in other pulmonary diseases. We

sought to characterize the EV phenotype within ARDS patient broncho-alveolar lavage fluid

(BAL), and to determine whether BAL EV could be utilized as a potential biomarker in ARDS.

BAL was collected from sepsis patients with and without ARDS, and from esophagectomy

patients post-operatively (of whom a subset later developed ARDS during hospital

admission). BAL EV were characterized with regards to size, number and cell of origin. Sepsis

patients with ARDS had significantly higher numbers of CD14⁺/CD81⁺ monocyte-derived BAL

EV than sepsis patients without ARDS (p=0.015). However, the converse was observed in

esophagectomy patients who later developed ARDS (p=0.003). Esophagectomy patients

who developed ARDS also had elevated CD31⁺/CD63⁺ and CD31⁺/CD81⁺ endothelial-derived

BAL EV (p≤0.02) compared to esophagectomy patients who did not develop ARDS. Further

studies are required to determine whether CD31⁺ BAL EV may be a predictive biomarker for

ARDS in esophagectomy patients. CD14⁺/CD81⁺ BAL EV numbers were significantly higher in

those patients with sepsis-related ARDS who died during the 30 days following ICU

admission (p=0.027). Thus, $CD14^{+}/CD81^{+}$ BAL EV are a potential biomarker for disease

severity and mortality in sepsis-related ARDS. These findings provide the impetus to further

elucidate the contribution of these EV to ARDS pathogenesis.

Key Words: Acute Respiratory Distress Syndrome, Sepsis, Extracellular Vesicles, Monocyte.

INTRODUCTION

Acute Respiratory Distress Syndrome (ARDS) is a hyper-inflammatory pulmonary disorder,

which most commonly develops following sepsis. Neutrophilic inflammation and alveolar-

capillary barrier damage lead to alveolar edema and refractory hypoxia, requiring prolonged

mechanical ventilation (1). Mortality remains high at 35-45% (2). Survivors have long-term

morbidity and increased risk of developing lung fibrosis. There is an urgent need to identify

novel therapeutic targets for ARDS, especially due to the evolving SARS-CoV-2 pandemic in

which ARDS is the main cause of mortality (3).

Extracellular vesicles (EV) are membrane-bound anuclear structures which constitute an

inter-cellular communication mechanism (4). EV allow targeted transfer of diverse biologic

cargo (including mitochondria, RNA, cytokines) between different cell types (5). Uptake of

EV can alter gene expression within host cells (6). The tetraspanins CD9, CD63 and CD81 are

transmembrane proteins commonly expressed on EV, and can be used to isolate EV in

acellular biofluids (7). There are two main subtypes of EV: exosomes and microvesicles.

Exosomes are 30-150nm in diameter and form by fusion of multi-vesicular bodies with the

plasma membrane. Microvesicles are 100-1000nm in diameter and form by outward

blebbing of the plasma membrane (4). With overlap in size and common markers (e.g.

tetraspanins), differentiating exosomes and microvesicles is challenging, however

Endosomal Sorting Complex Required for Transport (ESCRT) proteins such as syntenin are

candidate internal cargo markers specific to exosomes (8).

Recent evidence indicates that EV play an important role in ARDS pathogenesis by

promoting persistent inflammation. Pathogenic EV are released when human ex-vivo

perfused lungs are injured with E. coli; isolation of these EV and administration to uninjured

human lungs can also induce inflammatory lung injury (9). Murine models of

lipopolysaccharide lung injury have shown that EV transfer of microRNA cargo (e.g. miR-466)

to alveolar macrophages can increase inflammatory cytokine release (10). Recent studies

have indicated that CD14[†] BAL EV may be a potential biomarker for disease activity in COPD

(11).

We previously showed that alveolar macrophages isolated from patients with sepsis-related

ARDS have impaired efferocytosis (ability to clear apoptotic cells) compared to control

ventilated sepsis patients without ARDS (12). Alveolar macrophage efferocytosis negatively

correlated with alveolar neutrophil apoptosis, and broncho-alveolar lavage (BAL) cytokines

IL-8 and IL- 1α . Impaired efferocytosis was associated with increased 30-day mortality and

duration of mechanical ventilation, indicating that this alveolar macrophage functional

defect contributes to ARDS pathogenesis (12). Treatment of healthy alveolar macrophages

with BAL from ARDS patients also impairs efferocytosis and downregulates Rac1 expression

(which causes cytoskeletal rearrangement allowing apoptotic cell engulfment), reproducing

the same functional defect observed in ARDS (13). However, the causative

immunomodulatory factors within ARDS patient BAL remain to be identified. Identification

of differentially expressed EV populations within ARDS BAL may guide further investigation

into the mechanism of this alveolar macrophage functional defect

In this study, the objective was characterize the EV phenotype in the BAL of patients with

sepsis-related ARDS and to compare this EV population to that in control sepsis patients and

in post-esophagectomy patients (a subset of whom later developed ARDS). We also aimed

to determine whether BAL EV could be utilized as a potential biomarker in sepsis-related

ARDS.

MATERIALS AND METHODS

Ethical Approval

As previously described (12), ethical approval was obtained to recruit ventilated sepsis

patients with and without ARDS (REC 16/WA/0169). Ethical approval was also obtained to

recruit patients undergoing transthoracic esophagectomy for esophageal carcinoma (REC

12/WM/0092) in the VINDALOO trial (14, 15). For patients who lacked capacity, permission

to enroll was sought from a personal legal representative in accordance with the UK Mental

Capacity Act (2005). For patients with capacity, written informed consent was obtained

from the patient.

Patient recruitment and broncho-alveolar lavage

Invasively ventilated adult sepsis patients with and without ARDS were recruited from the

intensive care unit of the Queen Elizabeth Hospital Birmingham, U.K. from December 2016 -

February 2019 and BAL was collected as previously described, within 48 hours of initiation

of mechanical ventilation (12). Patient demographic and physiological details are in this

prior publication. In the VINDALOO trial (15), patients underwent post-operative

bronchoscopy and BAL following esophagectomy. Following unblinding of the study, those

patients who received placebo were identified; BAL samples from the 4 patients who

developed ARDS during their post-operative course and 8 patients who did not develop

ARDS were analyzed in this study. For all patients, sterile, isotonic saline (2 x 50ml aliquots)

was instilled into a sub-segmental bronchus of the lingula or right middle lobe. Recovery

ranged between 20 - 60 ml and did not differ between patient groups. BAL fluid collection

was standardized across all patients in keeping with European guidelines (16).BAL fluid was

rendered acellular by centrifuging at 500g for 5 minutes then stored at -80°C in aliquots

prior to use in this study. Differential cell count was performed on cells isolated from BAL.

BAL Extracellular Vesicle characterization

A single-particle interferometric reflectance image sensing platform was used (Exoview

R100 reader, NanoView Biosciences, USA) to detect and characterize EV size, number and

surface marker expression within BAL samples (17). The Exoview platform allows

quantification and phenotyping of EV ≥50nm in diameter (7). EV numbers in BAL were

measured using ExoView Tetraspanin kits (NanoView Biosciences) according to

manufacturer's instructions. Each spot on an Exoview Tetraspanin chip is an independent

test, interacting with only a small volume surrounding itself. Accounting for volume and spot

size, a normalized particle number can be generated and when multiplied by the dilution

factor and a correction factor of 10⁴, data can be expressed as EV/ml. Each spot on an

Exoview Tetraspanin chip has the capacity to bind up to 5000 EVs before becoming

saturated. According to the manufacturer's instructions, at least a 1:1 dilution of any

biofluid with incubation solution is required prior to incubation on Exoview Tetraspanin

chips. Preliminary studies had found that use of dilutions lower than 1:20 resulted in chip

saturation, with the number of EVs exceeding the chip binding capacity. BAL samples were

therefore diluted 1:20 with incubation solution to prevent chip saturation. 35 µl of diluted

BAL was loaded on the ExoView Tetraspanin chips and incubated for 16 hours in a sealed,

humidified 24-well plate at room temperature to allow EV binding. Each chip contained

spots printed with mouse anti-human antibodies against the tetraspanins CD63 (clone

H5C6), CD81 (clone JS81) and CD9 (clone H19a) which enabled EV capture. Chips also

contained spots with mouse $IgG1\kappa$ matching isotype antibodies, used as a control for non-

specific EV binding. Chips were washed thrice with incubation solution; after each wash

plates were shaken at 500rpm (LSE digital microplate shaker, Corning, USA). Chips were

then stained with a fluorescent antibody cocktail for 1 hour at room temperature in the dark

to characterize EV surface markers. Fluorophore-conjugated mouse anti-human antibodies

included: CD14-Allophycocyanin (1:100 dilution, clone 61D3, Invitrogen), CD206-

Phycoerythrin (1:100 dilution, clone 19.2, Invitrogen), EpCam-AlexaFluor488 (1:400 dilution,

clone 94C, BioLegend), CD66b-AlexaFluor647 (1:200 dilution, clone G10F5, BD Biosciences),

CD31-Phycoerythrin (1:100 dilution, clone WM59, Invitrogen), and CD41-AlexaFluor488

(1:400 dilution, clone HIP8, BioLegend). Chips were washed thrice again, with a final wash in

distilled water, before being imaged using the ExoView R100 reader and nScan2 v2.76

software. Data were analyzed using NanoViewer v2.82, utilizing mouse IgG capture spots as

negative control (indicative of non-specific binding) for fluorescent gating, and EV sizing

thresholds set at 50-200nm diameter. EV cell origin data were correlated with previously

recorded clinical outcomes and immune cell functional parameters (12). Data from each

tetraspanin capture spot (CD63, CD81 and CD9) were calculated by subtracting negative

control values from IgG spots.

Statistical Analysis

Data were analyzed using Prism 8 software (GraphPad, USA). Parametric data shown as

mean and standard deviation. Non-parametric data shown as median and interquartile

range. Differences between continuously distributed non-parametric data assessed using

Mann-Whitney tests. Differences between three or more unpaired non-parametric data sets

assessed using Kruskal-Wallis test by ranks. Two-tailed p-values of ≤0.05 were considered

significant.

RESULTS

The demographic and clinical characteristics of ARDS and control patients from the two

cohorts analyzed are shown in **Table 1**. BAL samples were analyzed from 17 sepsis patients

with ARDS, 14 sepsis patients without ARDS, 4 esophagectomy patients who later developed

ARDS and 8 esophagectomy patients who did not develop ARDS.

BAL EV were characterized with regards to size, number and surface marker expression to

indicate cellular origin. The size distribution of BAL EV did not differ across patient groups

(Figure 1A). Representative fluorescence images from the Exoview platform demonstrating

EV surface marker expression and lack of non-specific binding are shown in Figure 1B-E.

Characterization studies showed that a greater number of monocyte-derived CD14⁺/CD81⁺

EV were present in the BAL of sepsis patients with ARDS compared to sepsis patients

without ARDS (Figure 2A, medians 1.23×10^8 /ml vs 6.26×10^7 /ml, p=0.015). However in

esophagectomy patients, those who subsequently developed ARDS had lower CD14⁺/CD81⁺

BAL EV counts compared to patients who did not develop ARDS (Figure 2A, medians 3.96

 $\times 10^7$ /ml vs 9.94 $\times 10^7$ /ml, p=0.03). Endothelial-derived CD31 $^+$ /CD63 $^+$ and CD31 $^+$ /CD81 $^+$ BAL

EV were elevated in esophagectomy patients who subsequently developed ARDS compared

to those who did not develop ARDS (Figure 2B, p≤0.02). There were no differences in the

numbers of CD66b⁺, CD41⁺, CD206⁺ and EpCam⁺ BAL EV between ARDS and control groups

in both cohorts (Figure 2C-F).

In sepsis patients with ARDS, those who died within 30 days of ICU admission had a greater

number of CD14⁺/CD81⁺ BAL EV than survivors (Figure 3A, medians 3.43 x10⁸ /ml vs 9.54

 $\times 10^7$ /ml, p=0.027), however there is overlap between groups. Across all sepsis patients with

and without ARDS, CD66b⁺/CD63⁺ BAL EV correlated directly with BAL interleukin (IL)-8

concentrations, (Figure 3B, r=0.751, p<0.0001). Across all sepsis patients with and without

ARDS, CD66b⁺/CD63⁺ BAL EV correlated inversely with alveolar macrophage efferocytosis

index (**Figure 3C**, r=-0.612, p=0.0025).

DISCUSSION

In this study, sepsis patients with ARDS had significantly higher numbers of CD14⁺/CD81⁺

BAL EV than sepsis patients without ARDS. CD14⁺/CD81⁺ BAL EV numbers were significantly

higher in those patients with sepsis-related ARDS who died during the 30 days following ICU

admission. CD206⁺ EV numbers were unchanged in sepsis-related ARDS patients (CD206

being an alveolar macrophage marker), indicating that the increased CD14⁺ EV observed in

ARDS patients were derived from infiltrating monocytes as opposed to resident alveolar

macrophages. CD14 has previously been used as a marker of monocyte-derived EV (18). The

relationship between CD14⁺/CD81⁺ BAL EV and mortality in sepsis-related ARDS patients is

in keeping with previous studies showing that the degree of monocyte influx in ARDS can

correlate with the severity of respiratory failure (19). Previous studies have shown that

monocyte-derived plasma EV containing gasdermin D and activated caspase-1 are more

abundant in patients with sepsis-related ARDS compared to healthy controls; uptake of

these EV can induce human pulmonary vascular endothelial cell death (20). This data supports our hypothesis that CD14⁺ EV may contribute to ARDS pathogenesis, and might be utilized as a biomarker of disease severity. Within the sepsis-related ARDS cohort, there appear to be two distinct subpopulations of BAL CD14⁺ EV numbers: 'high' and 'low' (Figure 2A). These may reflect different ARDS phenotypes (21), with the 'high' CD14⁺ EV subpopulation indicating a hyper-inflammatory phenotype, and the 'low' subpopulation indicating a hypo-inflammatory phenotype; however further analysis of BAL fluid and physiological data would be required to confirm this. Conversely, CD14⁺/CD81⁺ BAL EV counts were decreased in esophagectomy patients who later developed ARDS compared to controls. BAL samples from esophagectomy patients were taken immediately postoperatively prior to the development of ARDS, compared to being taken at the time of ARDS diagnosis in sepsis patients. This temporal difference in sampling and differences in the etiology of ARDS between the two cohorts may partially explain the divergent CD14⁺/CD81⁺ BAL EV counts. However, due to low n-numbers in the post-esophagectomy ARDS group, firm conclusions cannot be made and further appropriately powered studies are required to investigate the predictive role of CD14⁺/CD81⁺ BAL EV in esophagectomy patients.

We also observed associations between CD66b⁺/CD63⁺ neutrophil-derived BAL EV in sepsis patients and increased BAL IL-8 concentration and decreased alveolar macrophage efferocytosis. These data indicate that CD66b⁺/CD63⁺ BAL EV may be a marker of inflammation in sepsis-related ARDS. Neutrophil-derived EV have been shown to have an anti-inflammatory, tolerogenic effect following uptake by macrophages and T lymphocytes (22-25). Previous studies have also reported that neutrophil-derived EV can transfer microRNA-223 to alveolar epithelial cells, which reduces protein permeability and cytokine release via repression of poly[adenosine diphosphate—ribose] polymerase—1 (26). Therefore,

the increased number of CD66b⁺ EV in patients with a more inflammatory alveolar

microenvironment may be a compensatory protective response to suppress inflammation

and reduce alveolar epithelial injury.

Our findings of increased CD31⁺/CD63⁺ and CD31⁺/CD81⁺ endothelial-derived EV in

esophagectomy patients who subsequently developed ARDS may indicate an early signal of

pulmonary endothelial injury resulting from one-lung ventilation detectable immediately

post-operatively. This endothelial injury may initiate the development of ARDS in

esophagectomy patients. Murine studies have shown that ventilator-induced lung injury can

increase endothelial EV shedding (27); endothelial-derived EVs have been shown to induce

acute lung injury by promoting neutrophil infiltration, endothelial dysfunction and pro-

inflammatory cytokine release (28, 29). Appropriately powered future studies are required

to further investigate the role of CD31⁺ EV as a predictive biomarker in esophagectomy

patients. No difference in CD31⁺ and CD41⁺ EVs were observed between sepsis patients with

and without ARDS. It is also important to note that the process of BAL dilutes the alveolar

epithelial lining fluid by approximately 100-fold, which may account for BAL EV numbers

being lower than EV numbers detected in other biofluids.

EV transfer of microRNA cargo to murine macrophages can alter metabolic profile

and function (30); EV transfer of long non-coding RNA can promote glycolysis (31). An

association between impaired alveolar macrophage efferocytosis and dependence on

glycolysis has been observed in COPD patients (32). Further studies are required to

determine if similar pathological processes occurs in ARDS, specifically whether CD14⁺ EV

transfer of microRNA or protein cargo induces alveolar macrophage dysfunction (12),

thereby promoting persistent inflammation. Understanding the role of EV in ARDS

pathogenesis will allow identification of potential EV / microRNA biomarkers and novel

therapeutic targets for ARDS.

A limitation of our study is that while we identified EV from the major cell types

present in the alveolar space, not all cellular origins were included in our analysis (e.g.

dendritic cells, lymphocytes). Although tetraspanin capture of EVs provides greater

specificity compared to other isolation methods, it also limits phenotyping, and therefore

only provides an indication of the relevance of CD14⁺ EV. Another limitation is that we did

not capture EV based on CD14⁺, CD31⁺ and CD66b⁺ expression, which would allow probing

of external markers for extensive phenotyping. Future studies are required to undertake this

and probe for internal markers (e.g. syntenin) to determine EV biogenesis pathways. The

finding that CD14 most commonly co-localises with tetraspanin CD81, and CD66b with

tetraspanin CD63, may indicate different EV biogenesis pathways in monocytes and

neutrophils (33). A further limitation of our study is that the observed differences in CD14⁺

BAL EVs were modest, and it is unclear whether these differences are biologically relevant.

Similarly, correlations observed with CD14⁺, CD31⁺ and CD66b⁺ BAL EVs cannot be used to

draw conclusions on their functional roles. Further work is required to determine the

biological function of CD14⁺ and CD31⁺ BAL EV subpopulations in ARDS patients. Another

limitation of our study is that the number of VINDALOO trial patients who received placebo

and developed ARDS following esophagectomy was low (n=4), thus preventing us from

drawing firm conclusions regarding the role of EVs as biomarkers in this population.

In conclusion, we report that CD14⁺/CD81⁺ BAL EV are enriched in patients with

sepsis-related ARDS compared to controls, and that an elevated CD14⁺/CD81⁺ BAL EV count

is associated with increased mortality in ARDS patients, although the sample size is modest.

Thus, CD14⁺ BAL EV are a potential biomarker for disease severity and mortality in ARDS.

Our findings provide the impetus to further elucidate the role these EV play in ARDS pathogenesis.

Ethical Approval

Ethical approval was obtained to recruit ventilated sepsis patients with and without ARDS (REC 16/WA/0169). Ethical approval was also obtained to recruit patients undergoing transthoracic esophagectomy for esophageal carcinoma (REC 12/WM/0092) as previously described in the VINDALOO trial. For patients who lacked capacity, permission to enroll was sought from a personal legal representative in accordance with the UK Mental Capacity Act (2005). For patients with capacity, written informed consent was obtained from the patient.

Grants

This work was funded by Medical Research Council grants MR/N021185/1 (RYM) and MR/L002736/1 (DT/AS), and by National Heart, Lung and Blood Institute grants HL134828 (MAM) and HL140026 (MAM). The ExoView platform was funded by an EPSRC Capital award awarded to Dr. Sophie Cox, University of Birmingham.

Disclosures

No conflicts of interest, financial or otherwise, are declared by the authors.

Author Contributions

RYM, AS, DP, PH, MAM, and DRT contributed to study conception and design. RYM, JP, HL and STL contributed to data acquisition. JP and PH provided assistance and training for use of the Exoview platform. All authors contributed to the data analysis and interpretation. RYM, JP, and DRT drafted the manuscript. All authors critically revised the manuscript for intellectual content and approved the final version before submission.

Figure 1: BAL EV size distribution and representative Exoview fluorescence images

A) BAL EV size distribution measured using single-particle interferometric reflectance image sensing (Exoview R100 platform). Statistical analysis by Kruskal-Wallis test, n≥4 in each group. There was no significant difference in EV size distribution between sepsis patients with ARDS, sepsis patients without ARDS, esophagectomy patients who developed ARDS and esophagectomy patients who did not develop ARDS (p=0.123). EV measured between 150-200nm are not shown in this graph as these accounted for <1% of total EV population in all three groups. Panels B-D show representative Exoview fluorescence images demonstrating EV surface marker expression. B: Detection of CD66b⁺ EV (AlexaFluor647) on CD63 tetraspanin spot. C: Detection of EpCam⁺ EV (AlexaFluor488) on CD9 tetraspanin spot. D: Detection of CD31⁺ EV (Phycoerythrin) on CD9 tetraspanin spot. E: Representative Mouse IgG spot negative control showing low non-specific EV binding in BAL samples.

Figure 2: BAL EV surface marker expression in ARDS and control groups across sepsis and esophagectomy patient cohorts

BAL EV surface marker expression measured by tetraspanin antibody capture (CD9/63/81) and fluorescent antibody labelling via the Exoview R100 platform (EpCam for epithelial, CD66b for neutrophil, CD206 for alveolar macrophage, CD31 for endothelial, CD41 for platelet and CD14 for monocyte origin). All data expressed as median and inter-quartile range, n≥8 in each group. Statistical analyses by Mann-Whitney U tests. Fluorescence data is presented by individual tetraspanin capture spots. Data from each tetraspanin capture spot (CD9, CD63 and CD81 - first three columns from the left) were calculated by subtracting negative control values from mouse IgG spots (shown in the furthest panel to the right). A) Monocyte-derived CD14⁺/CD81⁺ BAL EV were elevated in sepsis patients with ARDS compared to sepsis patients without ARDS (medians 1.23×10^8 /ml vs 6.26×10^7 /ml, p=0.015). In esophagectomy patients, those who subsequently developed ARDS had lower CD14⁺/CD81⁺ BAL EV counts compared to patients who did not develop ARDS (medians 3.96 $x10^7$ /ml vs 9.94×10^7 /ml, p=0.03). B) Endothelial-derived CD31 $^+$ /CD63 $^+$ and CD31 $^+$ /CD81 $^+$ BAL EV were elevated in esophagectomy patients who subsequently developed ARDS compared to controls (p \leq 0.02). **C-F**) There were no differences in the numbers of CD66b † , CD41 † , CD206⁺ and EpCam⁺ EV between ARDS and control groups in both cohorts.

Figure 3: Correlations between BAL EV and clinical, biochemical and immune parameters

AM= Alveolar Macrophage. IL= Interleukin. **A)** In sepsis patients with ARDS, those who died within 30 days of ICU admission had a greater number of CD14 $^+$ / CD81 $^+$ BAL EV than survivors (medians 3.43 x10 8 /ml vs 9.54 x10 7 /ml, p=0.027, n=17). Statistical analysis by Mann-Whitney test, data shown as median and inter-quartile range. **B)** Across all sepsis patients, with and without ARDS, CD66b $^+$ / CD63 $^+$ BAL EV correlate directly with BAL IL-8 concentrations (r=0.751, p<0.0001, n=31). Statistical analyses by Spearman's correlation

coefficient. **C**) Across all sepsis patients, with and without ARDS, CD66b⁺/CD63⁺ BAL EV correlate inversely with AM efferocytosis index (r=-0.612, p=0.0025, n=31). Statistical analyses by Spearman's correlation coefficient.

REFERENCES

- 1. Matthay MA, Zemans RL, Zimmerman GA, Arabi YM, Beitler JR, Mercat A, Herridge M, Randolph AG, and Calfee CS. Acute respiratory distress syndrome. *Nature reviews Disease primers* 5: 18, 2019.
- 2. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, Ranieri M, Rubenfeld G, Thompson BT, Wrigge H, Slutsky AS, and Pesenti A. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. *Jama* 315: 788-800, 2016.
- 3. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, and Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *The Lancet Respiratory medicine* 8: 475-481, 2020.
- 4. **Mahida RY, Matsumoto S, and Matthay MA**. Extracellular Vesicles: A New Frontier for Research in Acute Respiratory Distress Syndrome. *American journal of respiratory cell and molecular biology* 63: 15-24, 2020.
- 5. **Shah R, Patel T, and Freedman JE**. Circulating Extracellular Vesicles in Human Disease. *The New England journal of medicine* 379: 958-966, 2018.
- 6. Gupta R, Radicioni G, Abdelwahab S, Dang H, Carpenter J, Chua M, Mieczkowski PA, Sheridan JT, Randell SH, and Kesimer M. Intercellular Communication between Airway Epithelial Cells Is Mediated by Exosome-Like Vesicles. *American journal of respiratory cell and molecular biology* 60: 209-220, 2019.
- 7. Khan NZ, Cao T, He J, Ritzel RM, Li Y, Henry RJ, Colson C, Stoica BA, Faden AI, and Wu J. Spinal cord injury alters microRNA and CD81+ exosome levels in plasma extracellular nanoparticles with neuroinflammatory potential. *Brain, behavior, and immunity* 92: 165-183, 2021.
- 8. Kugeratski FG, Hodge K, Lilla S, McAndrews KM, Zhou X, Hwang RF, Zanivan S, and Kalluri R. Quantitative proteomics identifies the core proteome of exosomes with syntenin-1 as the highest abundant protein and a putative universal biomarker. *Nature Cell Biology* 23: 631-641, 2021.
- 9. Liu A, Park JH, Zhang X, Sugita S, Naito Y, Lee JH, Kato H, Hao Q, Matthay MA, and Lee JW. Therapeutic Effects of Hyaluronic Acid in Bacterial Pneumonia in the Ex Vivo Perfused Human Lungs. *American journal of respiratory and critical care medicine* 2019.
- 10. Shikano S, Gon Y, Maruoka S, Shimizu T, Kozu Y, Iida Y, Hikichi M, Takahashi M, Okamoto S, Tsuya K, Fukuda A, Mizumura K, and Hashimoto S. Increased extracellular vesicle miRNA-466 family in the bronchoalveolar lavage fluid as a precipitating factor of ARDS. *BMC pulmonary medicine* 19: 110, 2019.
- 11. Bazzan E, Radu CM, Tinè M, Neri T, Biondini D, Semenzato U, Casara A, Balestro E, Simioni P, Celi A, Cosio MG, and Saetta M. Microvesicles in bronchoalveolar lavage as a potential biomarker of COPD. American journal of physiology Lung cellular and molecular physiology 320: L241-l245, 2021.
- 12. Mahida RY, Scott A, Parekh D, Lugg ST, Hardy RS, Lavery GG, Matthay MA, Naidu B, Perkins GD, and Thickett DR. Acute Respiratory Distress Syndrome is associated with impaired alveolar macrophage efferocytosis. *The European respiratory journal* 2021.

- 13. Mahida RY, Scott A, Parekh D, Lugg ST, Belchamber KB, Hardy RS, Matthay MA, Naidu B, and Thickett DR. Assessment of alveolar macrophage dysfunction using an in vitro model of Acute Respiratory Distress Syndrome. *Front Med (Lausanne)* In Press., 2021.
- 14. Parekh D, Dancer RC, Lax S, Cooper MS, Martineau AR, Fraser WD, Tucker O, Alderson D, Perkins GD, Gao-Smith F, and Thickett DR. Vitamin D to prevent acute lung injury following oesophagectomy (VINDALOO): study protocol for a randomised placebo controlled trial. *Trials* 14: 100, 2013.
- 15. Parekh D, Dancer RCA, Scott A, D'Souza VK, Howells PA, Mahida RY, Tang JCY, Cooper MS, Fraser WD, Tan L, Gao F, Martineau AR, Tucker O, Perkins GD, and Thickett DR. Vitamin D to Prevent Lung Injury Following Esophagectomy-A Randomized, Placebo-Controlled Trial. *Critical care medicine* 46: e1128-e1135, 2018.
- 16. **Haslam PL, and Baughman RP**. Report of ERS Task Force: guidelines for measurement of acellular components and standardization of BAL. *The European respiratory journal* 14: 245-248, 1999.
- 17. **Price J, Gardiner C, and Harrison P**. Platelet-enhanced plasma: Characterization of a novel candidate resuscitation fluid's extracellular vesicle content, clotting parameters, and thrombin generation capacity. *Transfusion* 61: 2179-2194, 2021.
- 18. Wang GH, Lu J, Ma KL, Zhang Y, Hu ZB, Chen PP, Lu CC, Zhang XL, and Liu BC. The Release of Monocyte-Derived Tissue Factor-Positive Microparticles Contributes to a Hypercoagulable State in Idiopathic Membranous Nephropathy. *Journal of atherosclerosis and thrombosis* 26: 538-546, 2019.
- 19. Rosseau S, Hammerl P, Maus U, Walmrath HD, Schutte H, Grimminger F, Seeger W, and Lohmeyer J. Phenotypic characterization of alveolar monocyte recruitment in acute respiratory distress syndrome. *American journal of physiology Lung cellular and molecular physiology* 279: L25-35, 2000.
- 20. Mitra S, Exline M, Habyarimana F, Gavrilin MA, Baker PJ, Masters SL, Wewers MD, and Sarkar A. Microparticulate Caspase 1 Regulates Gasdermin D and Pulmonary Vascular Endothelial Cell Injury. *American journal of respiratory cell and molecular biology* 59: 56-64, 2018.
- 21. Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, and Matthay MA. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. *The Lancet Respiratory medicine* 2: 611-620, 2014.
- 22. Shen G, Krienke S, Schiller P, Nießen A, Neu S, Eckstein V, Schiller M, Lorenz HM, and Tykocinski LO. Microvesicles released by apoptotic human neutrophils suppress proliferation and IL-2/IL-2 receptor expression of resting T helper cells. *European journal of immunology* 47: 900-910, 2017.
- 23. **Eken C, Martin PJ, Sadallah S, Treves S, Schaller M, and Schifferli JA**. Ectosomes released by polymorphonuclear neutrophils induce a MerTK-dependent anti-inflammatory pathway in macrophages. *The Journal of biological chemistry* 285: 39914-39921, 2010.
- 24. **Gasser O, and Schifferli JA**. Activated polymorphonuclear neutrophils disseminate anti-inflammatory microparticles by ectocytosis. *Blood* 104: 2543-2548, 2004.
- 25. **Dengler V, Downey GP, Tuder RM, Eltzschig HK, and Schmidt EP**. Neutrophil intercellular communication in acute lung injury. Emerging roles of microparticles and gap junctions. *American journal of respiratory cell and molecular biology* 49: 1-5, 2013.
- 26. Neudecker V, Brodsky KS, Clambey ET, Schmidt EP, Packard TA, Davenport B, Standiford TJ, Weng T, Fletcher AA, Barthel L, Masterson JC, Furuta GT, Cai C, Blackburn MR, Ginde AA, Graner MW, Janssen WJ, Zemans RL, Evans CM, Burnham EL, Homann D, Moss M, Kreth S, Zacharowski K, Henson PM, and Eltzschig HK. Neutrophil transfer of miR-223 to lung epithelial cells dampens acute lung injury in mice. *Science translational medicine* 9: 2017.
- 27. Letsiou E, Sammani S, Zhang W, Zhou T, Quijada H, Moreno-Vinasco L, Dudek SM, and Garcia JG. Pathologic mechanical stress and endotoxin exposure increases lung endothelial microparticle shedding. *American journal of respiratory cell and molecular biology* 52: 193-204, 2015.


- 28. Buesing KL, Densmore JC, Kaul S, Pritchard KA, Jr., Jarzembowski JA, Gourlay DM, and Oldham KT. Endothelial microparticles induce inflammation in acute lung injury. *The Journal of surgical research* 166: 32-39, 2011.
- 29. Densmore JC, Signorino PR, Ou J, Hatoum OA, Rowe JJ, Shi Y, Kaul S, Jones DW, Sabina RE, Pritchard KA, Jr., Guice KS, and Oldham KT. Endothelium-derived microparticles induce endothelial dysfunction and acute lung injury. *Shock (Augusta, Ga)* 26: 464-471, 2006.
- 30. Park JE, Dutta B, Tse SW, Gupta N, Tan CF, Low JK, Yeoh KW, Kon OL, Tam JP, and Sze SK. Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift. *Oncogene* 38: 5158-5173, 2019.
- 31. Chen F, Chen J, Yang L, Liu J, Zhang X, Zhang Y, Tu Q, Yin D, Lin D, Wong PP, Huang D, Xing Y, Zhao J, Li M, Liu Q, Su F, Su S, and Song E. Extracellular vesicle-packaged HIF- 1α -stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. *Nature cell biology* 21: 498-510, 2019.
- 32. Ryan E, Coelho P, Cole J, Bewley M, Budd R, Callahan J, McCafferty J, Singh D, Dockrell D, Walmsley S, and Whyte M. T1 Defective metabolism drives macrophage dysfunction in COPD. *Thorax* 76: A1-A1, 2021.
- 33. Mathieu M, Névo N, Jouve M, Valenzuela JI, Maurin M, Verweij FJ, Palmulli R, Lankar D, Dingli F, Loew D, Rubinstein E, Boncompain G, Perez F, and Théry C. Specificities of exosome versus small ectosome secretion revealed by live intracellular tracking of CD63 and CD9. *Nature communications* 12: 4389, 2021.


Table 1: Patient demographic and clinical characteristics

	Sepsis Patients		Esophagectomy Patients	
	With ARDS (n=17)	Without ARDS (n=14)	Developed ARDS (n=4)	Did not develop ARDS (n=8)
Demographics				
Age in years:	59.2 (13.9)	55.1 (16.3)	63.3 (6.9)	65.8 (7.9)
Male Gender: n (%)	15 (71%)	11 (65%)	4 (100%)	4 (50%)
Ethnicity: Caucasian - n (%)	21 (100%)	17 (100%)	4 (100%)	7 (88%)
Smoking status: n (%)				
- Current	7 (33%)	5 (29%)	1 (25%)	0 (0%)
- Ex-smoker	9 (43%)	6 (35%)	1 (25%)	6 (75%)
 Never smoker 	2 (10%)	1 (6%)	2 (50%)	2 (25%)
- Unknown	3 (14%)	5 (29%)	0 (0%)	0 (0%)
ICU LoS in days:	23.0	12.0	9.5	4.5
median (IQR)	(12.8 - 33.8)	(7.5 - 19.0)	(5 - 22.3)	(2.5 - 7.8)

Hospital LoS in days:	33.0	24.0	22.0	12
median (IQR)	(15.3 – 52.5)	(13.0 – 39.5)	(17.3 – 53.8)	(8.3 – 15.8)
Inpatient Mortality: n (%)	7 (33.3%)	3 (17.6%)	1 (25%)	0 (0%)
BAL leukocyte count x10 ⁶ :	15.8	6.4	11.0	7.8
median (IQR)	(7.4 – 31.3)	(3.8 – 27.0)	(5.9 – 18.6)	(2.1 – 10.5)
% Neutrophils in BAL:	69.9 (21.5)	49.0 (30.6)	20 (20)	9.5 (10.1)

IQR = Interquartile range. LoS = Length of stay. ICU = Intensive care unit. Data are presented as mean (standard deviation) unless otherwise indicated.





Tetraspanin capture data corrected for mouse IgG controls Mouse IgG **Negative** Control CD81+ CD9+ CD63+ BAL EVs/ml p=0.003 Non-specific mouse IgG binding CD14*/CD81* BAL EVS CD14*/CD63* 107 **CD14+** 10 ARDS Control ARDS Control ARDS Control ARDS Control ARDS Control ARDS Control Sepsis Patients Esophagectomy Sepsis Patients Esophagectomy В BAL EVs/ml CD31*/CD81* BAL EVs / ml **CD31+** ARDS Control ARDS Control Sepsis Patients Esophagectomy ARDS Control ARDS Control Esophagectomy CD66b*/CD63* E CD66b+ ARDS Control ARDS Control ARDS Control Esophagectomy D */CD81* BAL EVs / 1 E/s 10 **CD41+** CD41+ ARDS Control ARDS Control Esophagectomy ARDS Control ARDS Control ARDS Control ARDS Control Sepsis Patients Esophagectomy Sepsis Patients Esophagectomy mouse IgG binding/ E EpCam*/CD81* BAL EVs. EpCam+ ARDS Control Sepsis Patients ARDS Control Esophagectomy ARDS Control ARDS Control ARDS Control ARDS Control ARDS Control ARDS Control Esophagectomy Sepsis Patients IgG binding CD206+ ARDS Control Esophagectomy ARDS Control ARDS Control ARDS Con ARDS Control ARDS Control Sepsis Patients Esophagectomy Control Sepsis Patients Esophagectomy

